Results 151 to 160 of about 36,124 (280)

Multimodal Framework in Lung Cancer Management: Integrating Liquid Biopsy with Traditional Diagnostic Techniques

Cancer Management and Research
Wenlong Qi,1 Lin Tian,2 Jianan Xu,2 Zhenyu Li,2 Tan Wang2 1Changchun University of Traditional Chinese Medicine, Changchun, Jilin, 130000, People’s Republic of China; 2Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun,
Qi W, Tian L, Xu J, Li Z, Wang T
doaj  

Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025

European Journal of Haematology, Volume 116, Issue 6, Page 724-732, June 2026.
ABSTRACT Minimal residual disease (MRD) is a central biomarker in multiple myeloma (MM), offering unprecedented sensitivity for evaluating treatment efficacy and serving as a potential surrogate endpoint. We conducted a comprehensive analysis of clinical trials registered on ClinicalTrials.gov between 2014 and 2025.
Mimi Choon‐Quinones, George Dennis Obeng, Benjamin Asiedu‐Ayeh, Sampson Kawuo, Asmau Mohammed Tukur, Inusah Mohammed, Akosua Pokuaah Obeng, Jean‐Luc Harousseau, Anja Seckinger, Dirk Hose, Emmanuel Sarkodie, Attila Imre, Marcell Csanádi   +12 more
wiley   +1 more source

Post‐surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection

International Journal of Cancer, Volume 158, Issue 10, Page 2771-2783, 15 May 2026.
What's New? Circulating nuclear DNA (cir‐nDNA)‐based assessment of minimal residual disease (MRD) offers powerful post‐surgery prognostic insight for stage III colon cancer (CC). Sparse knowledge of post‐surgical variations and origins in cir‐nDNA, however, has limited its clinical application.
Andrei Kudriavtsev, Saidi Daoud, Catalina Isabel Cofre Muñoz, Alexia Mirandola, Ekaterina Pisareva, Javier Gonzalo Ruiz, Marco Macagno, Nadia Saoudi Gonzalez, Evelyne Crapez, Marc Ychou, Ramon Salazar Soler, Elisabetta Fenocchio, Paula X. Fernandez Calotti, Thibault Mazard, Cristina Santos Vivas, Elena Elez, Federica Di Nicolantonio, Alain R. Thierry   +17 more
wiley   +1 more source

Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1457-1472, May 2026.
Abstract Aims This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization. Methods Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model ...
Alessandro De Carlo, Elena Maria Tosca, Mirjam Crul, Tim Schutte, Lia van Zuijlen, Idris Bahce, Medhat M. Said, Jan Buter, Harmen Huls, Paolo Magni, Imke Bartelink   +10 more
wiley   +1 more source

Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Purpose Patients with advanced epidermal growth factor receptor (EGFR)‐mutated adenocarcinoma often receive frontline first‐ and second‐generation EGFR tyrosine kinase inhibitor (TKI) treatments in Taiwan. However, upon progression, not all patients undergo rebiopsy for molecular testing.
Min‐Hsi Lin, Kuo‐An Chu, Chiu‐Fan Chen, You‐Cheng Jiang, Wei‐Cheng Hong, Ming‐Yen Hung, Chun‐Hsiang Hsu   +6 more
wiley   +1 more source

Identification of Prognostic Risk Factors in Older Patients With Extensive‐Stage Small Cell Lung Cancer

Cancer Medicine, Volume 15, Issue 5, May 2026.
The study corroborates the prognostic value of previously identified risk factors impacting progression‐free survival (PFS) and overall survival (OS) in older patients with extensive‐stage small cell lung cancer (ES‐SCLC). The figure was created with Microsoft PowerPoint.
Jiayin Liu, Xun Liu, Xiaolin Li, Ning Liu, Bo Wang, Li Feng, Zhisong Fan, Long Wang, Jing Han, Xue Zhang, Hui Jin, Dan Li, Yan Liu, Jing Zuo, Yudong Wang   +14 more
wiley   +1 more source

Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT The efficacy of PD‐1 inhibitor pucotenlimab (HX008) in solid tumors exhibits heterogeneity. This study integrated data from 6 clinical trials (covering gastric/gastroesophageal junction cancer, triple‐negative breast cancer, melanoma, and dMMR/MSI‐H solid tumors) using Bayesian meta‐analysis, machine learning (optimal XGBoost AUC = 0.86), and ...
Yingge He, Changqing Gao, Shiyan Zhang, Yonghui Hao, Shuning He, Ke Peng, Liqi Li   +6 more
wiley   +1 more source

Clinical Significance of Biomarkers in Oropharyngeal Squamous Cell Carcinoma: Recurrence Prediction and Treatment Response

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Oropharyngeal squamous cell carcinoma (OPSCC) accounts for a substantial proportion of head and neck cancers, with a rising incidence largely driven by human papillomavirus (HPV) infection. Despite advances in multimodal treatment, disease recurrence remains common and limits long‐term survival, highlighting the need for reliable ...
Yunxia Chen, Wenyu Zhang, Xiang Gao, Kongling Xing, Yijing Ren, Jinyu Hu, Zhihao Xie, Ping Zhou   +7 more
wiley   +1 more source

Integration of circulating tumor DNA profiling in the risk stratification of classical Hodgkin lymphoma in children, adolescents, and young adults. [PDF]

Hemasphere
Simonin M, Viennot M, Haouy S, Ducassou S, Curtillet C, Garnier N, Phulpin A, Paillard C, Rigaud C, Couec ML, Carausu L, Bonneau J, Pellier I, Barbati M, Millot F, Dourthe MÉ, Kanold J, Schneider P, Stephan JL, Leglise C, Pluchart C, Viailly PJ, Michel V, Boudjemaa S, Jonca B, Leblanc T, Landman-Parker J, Jardin F.   +27 more
europepmc   +1 more source

Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Neoadjuvant disitamab vedotin combined with camrelizumab and S‐1 achieved high pathological response rates with manageable safety in resectable HER2‐overexpressing gastric and gastroesophageal junction cancer. Longitudinal circulating tumour DNA methylation profiling enabled dynamic monitoring of molecular response during treatment.
Longgang Wang, Bing Liu, Luguang Liu, Liqing Liu, Rong Li, Shumei Han, Xu Sun, Bo Bi, Yuanlin Sun, Dong Sun, Jie Chai   +10 more
wiley   +1 more source